EYSUVIS Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which patents cover Eysuvis, and what generic alternatives are available?
Eysuvis is a drug marketed by Kala Pharms Inc and is included in one NDA. There are thirteen patents protecting this drug.
This drug has seventy-nine patent family members in twelve countries.
The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis
A generic version of EYSUVIS was approved as loteprednol etabonate by AKORN on April 17th, 2019.
Summary for EYSUVIS
| International Patents: | 79 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Clinical Trials: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for EYSUVIS |
| What excipients (inactive ingredients) are in EYSUVIS? | EYSUVIS excipients list |
| DailyMed Link: | EYSUVIS at DailyMed |
Recent Clinical Trials for EYSUVIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kala Pharmaceuticals, Inc. | Phase 4 |
| Price Vision Group | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS
US Patents and Regulatory Information for EYSUVIS
EYSUVIS is protected by thirteen US patents and one FDA Regulatory Exclusivity.
Patents protecting EYSUVIS
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
FDA Regulatory Exclusivity protecting EYSUVIS
NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Kala Pharms Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EYSUVIS
See the table below for patents covering EYSUVIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 6816064 | See Plans and Pricing | |
| South Korea | 20150006869 | PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT | See Plans and Pricing |
| South Korea | 20210013339 | PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
